Pulmonx (NASDAQ:LUNG) CEO Sells $94,653.32 in Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 41,882 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total value of $94,653.32. Following the sale, the chief executive officer directly owned 1,137,936 shares in the company, valued at approximately $2,571,735.36. The trade was a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Trading Down 2.2%

Shares of LUNG stock opened at $2.21 on Friday. The firm has a 50-day moving average price of $1.82 and a 200 day moving average price of $1.57. Pulmonx Corporation has a twelve month low of $1.13 and a twelve month high of $2.89. The company has a market capitalization of $94.92 million, a price-to-earnings ratio of -1.91 and a beta of 0.34. The company has a current ratio of 4.32, a quick ratio of 3.52 and a debt-to-equity ratio of 0.95.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $22.76 million for the quarter, compared to analysts’ expectations of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Research analysts forecast that Pulmonx Corporation will post -1.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulmonx

A number of large investors have recently bought and sold shares of LUNG. R Squared Ltd acquired a new position in shares of Pulmonx in the 1st quarter valued at $26,000. Cerity Partners LLC purchased a new position in shares of Pulmonx in the 4th quarter worth $27,000. Opal Capital LLC purchased a new position in shares of Pulmonx in the 4th quarter worth $29,000. Jain Global LLC acquired a new position in Pulmonx in the third quarter valued at $30,000. Finally, Sei Investments Co. purchased a new stake in Pulmonx during the first quarter valued at about $31,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Trending Headlines about Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Analyst Ratings Changes

Several research firms have recently issued reports on LUNG. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.